FDA recall record

Lamotrigine Tablets, USP, 100 mg recall — FDA D-0833-2020

Cross Contamination; Lamotrigine Tablets 100 mg USP was contaminated with enalapril maleate.

Class Iclassification
D-0833-2020official record ID
Feb 19, 2020report date

Recall record at a glance

Official recordD-0833-2020
CategoryDrug Recalls
ClassificationClass I
FDA record statusTerminated
Recalling firmTaro Pharmaceuticals U.S.A., Inc.
Report dateFeb 19, 2020
Recall initiation dateDec 20, 2019
LocationHawthorne, NY, United States

Official product description

Lamotrigine Tablets, USP, 100 mg, Rx Only, 100-count bottle, Mfd. by: Taro Pharmaceutical Industries Ltd. Haifa Bay, Israel 2624761 Dist. by: Taro Pharmaceuticals U.S.A., Inc. Hawthorne, NY 10532, NDC 51672-4131-1.

Why the product was recalled

Cross Contamination; Lamotrigine Tablets 100 mg USP was contaminated with enalapril maleate.

Distribution information

Nationwide in the U.S. and Puerto Rico.

How to read the classification

FDA Class I indicates a situation in which there is a reasonable probability that use of or exposure to the product will cause serious adverse health consequences or death. The classification shown here comes directly from the FDA enforcement record.

Additional record details

Recall type: Voluntary: Firm initiated. Initial notification: Letter.

What to do next

If you believe you have the recalled product, use the recall number and firm information above to confirm the official notice and follow the instructions issued by the FDA, recalling firm, retailer or product manufacturer. For drugs and medical devices, decisions about treatment or medical care should be discussed with a qualified health professional.

About this record

Recall Lookup USA preserves the most complete source information successfully retrieved. We do not create missing facts or infer affected lots or VINs. The official record may still change, so use the identifier above when verifying current instructions.

FDA source limitation: openFDA enforcement reports are a reference dataset, not a live public-alert or recall-lifecycle service. FDA notes that enforcement-report status may not be updated after classification. Confirm current actions with the FDA, recalling firm or appropriate healthcare professional when relevant.

Related recall records

Other records from the same recalling company are shown first when available.